论文部分内容阅读
自从1913年Anitschkow等成功地制作实验性动脉硬化模型以来,血脂与动脉硬化之间的关系早已被人们熟知。近年来,高密度脂蛋白(HDL)作为抗冠心病保护因子又引起人们极大的兴趣。随着人们对脂蛋白代谢认识的深入,脂质与疾病关系的概念也正在变迁。以往对高脂血症的治疗多重视降低血浆总胆固醇(TC)和甘油三酯(TG),或低密度脂蛋白(LDL)和极低密度脂蛋白(VLDL)水平上,看来这种认识也未必完全正确,有愈来愈多的证据促使人们开始对以往治疗方法进行反省,有转变到设法提高HDL或HDL—胆固醇(HDL—C)浓度方面的趋向。
The relationship between lipids and atherosclerosis has long been well known since Anitschkow et al. Successfully produced experimental models of atherosclerosis in 1913. In recent years, high-density lipoprotein (HDL) as a protective factor against coronary heart disease has aroused great interest. As people’s understanding of lipoprotein metabolism deepens, the concept of lipid and disease is also changing. In the past, this treatment of hyperlipidemia has been shown to reduce multiple levels of plasma TC and TG, or LDL and VLDL levels It may not be entirely correct, and there is growing evidence that motivates people to reflect on previous treatments and to try to increase their HDL or HDL-C concentrations.